Motley Fool Money cover image

Show Business is Back in Business!

Motley Fool Money

00:00

Eli Lilly's Market Strategy and Weight Loss Drugs

This chapter explores Eli Lilly's financial performance, emphasizing the significance of its new weight loss drug ZepBound in comparison to existing treatments. It also critiques the exaggerated claims made about these medications while analyzing Gartner and Axon's market dynamics.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app